Combined, these findings suggest that the pharmacological activation of Sirt1 may be a promising therapeutic strategy for inflammation-induced, depression-associated phenotypes (Salminen et al., 2008; Yao and Rahman, 2012; Xie et al., 2013). This evidence concerns the gene SIRT1 and depressive symptom measurement.